Helmholtz-zentrum Fuer Infektionsforschung Gmbh

Helmholtz-zentrum Fur Infektionsforschung Gmbh

Gbf Gesellschaft Fur Biotechnologische Forschung Mbh

Peter Muhlradt

Carlos Alberto Guzman

Michael Morr

Armin Braun

Henning Weigt

Norbert Krug

Disclosed is the use of lipopeptides and lipoproteins as mucosal adjuvants for various vaccinations via mucous membranes, particularly intranasally. Said lipopeptides represent peptides or proteins substituted with 2,3-diacyloxy(2R)-propyl at the amino-terminal cystein of a peptide or protein, preferably S-(2,3-bis-palmitoyloxy-(2R)-propyl)cysteinyl peptides derived from mycoplasmas. Said peptides are highly effective even in small doses, produce good immunization results, and increase the IgA level, among others.

Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations

The present invention relates to a method for the preparation of a therapeutical composition, in particular, the present invention relates to a method for treating dendritic cells with a combination of at least one interferon gamma receptor agonist and at least one toll like receptor 2 and/or TLR 6 agonist and using these pretreated dendritic cells for the preparation of a therapeutical composition. Moreover, the present invention relates to a therapeutical composition containing dendritic cells and the use thereof for the treatment of various diseases and disorders.

Therapeutical composition containing dentritic cells and use thereof

The invention provides lipopeptide conjugates in which a cysteine that is double-substituted by a fatty acid is bonded by means of the carboxyl group to a highly soluble, physiologically compatible and non-immunogenic, polymeric conjugate group. The conjugates exhibit an excellent macrophage stimulant action and do not require addition solutizing. They can be used in a wide range of applications, in particular for stimulating macrophages, for stimulating antibody synthesis, for combating infection, as an immunostimulant, in particular in relation to tumors, for preventing and treating septicaemic shock, for would healing and as an adjuvant for vaccines.

Bisacyloxypropylcysteine conjugates and the use thereof

Growing community of inventors

Braunschweig, Germany

Peter Muhlradt